Related Experiment Videos
Osteogenin (bone morphogenic protein 3) inhibits proliferation and stimulates differentiation of osteoprogenitors in
J Amédée1, R Bareille, F Rouais
1INSERM-U. 306, Université de Bordeaux II, France.
Abstract:
Treatment of human bone marrow osteoprogenitors with osteogenin (BMP-3; at 1, 2.5 and 10 ng/ml) caused dose- and time-dependent inhibition of DNA synthesis and cell proliferation. Simultaneously, osteogenin stimulated type I collagen synthesis and cAMP production. Addition of osteogenin to the cell culture increased intracellular alkaline phosphatase activity and osteocalcin synthesis, with maximal stimulation at 2.5 ng/ml. Simultaneous addition of 2.5 ng/ml osteogenin and 1,25 dihydroxy vitamin D3 (10(-8) M) enhanced the stimulation observed in osteocalcin synthesis. The experiments reported here demonstrate the significant "in vitro" influence of osteogenin in the stimulation of osteogenic phenotype in osteoprogenitor cells which have been isolated from human bone marrow and cloned. These results support a reciprocal relationship between cell growth inhibition and expression of osteoblast differentiation.
Insights
Osteogenin (BMP-3) inhibits human bone marrow osteoprogenitor cell proliferation while stimulating osteoblast differentiation markers like collagen and osteocalcin. This suggests a link between reduced cell growth and increased osteogenic expression.
Area of Science:
- Biochemistry
- Cell Biology
- Orthopedics
Background:
- Osteoprogenitor cells are crucial for bone formation.
- Understanding factors that regulate osteoblast differentiation is key for bone regeneration therapies.
Purpose of the Study:
- To investigate the in vitro effects of osteogenin (BMP-3) on human bone marrow osteoprogenitor cells.
- To explore the relationship between osteogenin's impact on cell proliferation and osteogenic differentiation.
Main Methods:
- Human bone marrow osteoprogenitor cells were cultured and treated with varying concentrations of osteogenin (BMP-3).
- Assays measured DNA synthesis, cell proliferation, type I collagen synthesis, cAMP production, alkaline phosphatase activity, and osteocalcin synthesis.
- Cells were also treated with osteogenin in combination with 1,25 dihydroxy vitamin D3.
Main Results:
- Osteogenin inhibited DNA synthesis and cell proliferation in a dose- and time-dependent manner.
- Osteogenin stimulated type I collagen synthesis, cAMP production, intracellular alkaline phosphatase activity, and osteocalcin synthesis.
- Maximal stimulation of osteocalcin synthesis occurred at 2.5 ng/ml osteogenin.
- Combined treatment with osteogenin and 1,25 dihydroxy vitamin D3 further enhanced osteocalcin synthesis.
Conclusions:
- Osteogenin significantly influences the osteogenic phenotype of cloned human bone marrow osteoprogenitor cells in vitro.
- A reciprocal relationship exists between osteogenin-induced inhibition of cell growth and the expression of osteoblast differentiation markers.